CoDiagnostics (CODX)
(Real Time Quote from BATS)
$1.19 USD
+0.08 (7.21%)
Updated Apr 29, 2024 02:24 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for CoDiagnostics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 59 | 81 | 90 | 47 | 1 |
Receivables | 0 | 5 | 21 | 12 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 5 | 2 | 8 | 0 |
Other Current Assets | 2 | 1 | 2 | 1 | 0 |
Total Current Assets | 62 | 93 | 115 | 68 | 2 |
Net Property & Equipment | 3 | 3 | 2 | 1 | 0 |
Investments & Advances | 1 | 1 | 1 | 2 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 26 | 27 | 42 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 95 | 123 | 160 | 71 | 2 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 4 | 4 | 0 |
Income Taxes Payable | 0 | 0 | 2 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 6 | 0 | 0 |
Total Current Liabilities | 6 | 4 | 13 | 5 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 4 | 8 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 5 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 9 | 26 | 5 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 97 | 88 | 80 | 49 | 27 |
Retained Earnings | 5 | 40 | 54 | 18 | -25 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 16 | 14 | 0 | 0 | 0 |
Total Shareholder's Equity | 86 | 115 | 134 | 67 | 2 |
Total Liabilities & Shareholder's Equity | 95 | 123 | 160 | 71 | 2 |
Total Common Equity | 86 | 115 | 134 | 67 | 2 |
Shares Outstanding | 30.50 | 30.90 | 28.80 | 28.20 | 17.30 |
Book Value Per Share | 2.82 | 3.71 | 4.67 | 2.37 | 0.10 |
Fiscal Year End for CoDiagnostics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 59 | 63 | 69 | 75 |
Receivables | NA | 0 | 2 | 3 | 4 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 2 | 5 | 5 | 5 |
Other Current Assets | NA | 2 | 1 | 1 | 1 |
Total Current Assets | NA | 62 | 71 | 77 | 86 |
Net Property & Equipment | NA | 3 | 3 | 3 | 3 |
Investments & Advances | NA | 1 | 1 | 1 | 1 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 4 | 2 | 0 |
Intangibles | NA | 26 | 26 | 27 | 27 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 95 | 109 | 113 | 117 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 2 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 2 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 1 |
Total Current Liabilities | NA | 6 | 5 | 5 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 1 | 1 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 9 | 9 | 9 | 6 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 97 | 95 | 93 | 91 |
Retained Earnings | NA | 5 | 19 | 25 | 34 |
Other Equity | NA | 0 | 1 | 1 | 0 |
Treasury Stock | NA | 16 | 15 | 15 | 15 |
Total Shareholder's Equity | NA | 86 | 99 | 103 | 111 |
Total Liabilities & Shareholder's Equity | NA | 95 | 109 | 113 | 117 |
Total Common Equity | 0 | 86 | 99 | 103 | 111 |
Shares Outstanding | 31.20 | 30.50 | 30.70 | 30.20 | 30.90 |
Book Value Per Share | 0.00 | 2.82 | 3.24 | 3.42 | 3.58 |